PEPTARA LABS
Get Started

Compounded Tirzepatide

Compounded Tirzepatide

Sold out

Peptara Labs sold out of Tirzepatide on August 31, 2026. Those were the final vials, and there will be no more.

The compounding explainer below is unaffected: it is about the FDA framework and the brand products, not about our catalog.
See other metabolic research peptides

The short answer

Compounded tirzepatide is a version of the drug prepared by a licensed pharmacy rather than manufactured and sold as an approved brand product. It is not FDA-approved. It became widely available while tirzepatide was on the FDA drug shortage list, when compounders were permitted to help meet demand, and the basis for large-scale compounding narrowed following the FDA shortage-list decision. It is distinct from brand tirzepatide, sold as Zepbound and Mounjaro, and from research-grade material. Peptara Labs is not a pharmacy and has sold out of tirzepatide, so nothing here is an offer. This page is educational and not medical advice.

This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.

What is compounded tirzepatide? (503A and 503B)

Compounding is the practice of preparing a medication to fit a specific patient rather than dispensing a mass-manufactured product. In the federal compounding framework, section 503A covers traditional pharmacies that compound for an individual patient against a prescription, and section 503B covers registered outsourcing facilities that can prepare larger batches under stricter manufacturing controls.

In either case the result is not an FDA-approved drug. Compounding is generally intended to meet a documented need, for example a different strength or a formulation without an ingredient a patient reacts to, rather than to copy a commercially available approved product. That distinction is central to why the compounded tirzepatide situation changed.

How compounded tirzepatide differs from brand and from research-grade material

Brand tirzepatide, sold as Zepbound for weight management and Mounjaro for type 2 diabetes, has completed FDA review for those named uses. Compounded tirzepatide shares the active ingredient but has not been through that review, so the oversight is at the pharmacy level rather than at the level of an approved product.

Research-grade tirzepatide is a third category again. It is reference material sold for laboratory research use only, not for human use, and it is not a medicine of any kind. Peptara Labs sits in this third category. The safeguard that matters for research-grade material is a third-party certificate of analysis for each batch, which is a different assurance from the clinician-and-pharmacy chain that governs the prescription lane.

Why availability changed after the shortage

While tirzepatide sat on the FDA drug shortage list, compounding was permitted to help patients who could not get the brand product. That is what made compounded tirzepatide so easy to find for a period.

Following the FDA shortage-list decision that the tirzepatide shortage was resolved, the basis for widespread compounding narrowed, because compounding a copy of an available approved drug is generally not permitted. The exact timing, and how the transition applied to traditional pharmacies versus outsourcing facilities, is set by the FDA and has shifted over time. If you need the current status, confirm it against FDA guidance directly rather than relying on a date in an article.

What about compounded semaglutide?

Compounded semaglutide follows the same pattern for a different molecule. Semaglutide is a single GLP-1 receptor agonist sold under the brands Ozempic and Wegovy, where tirzepatide is a dual GLP-1 and GIP agonist.

The regulatory logic is identical: compounded semaglutide is pharmacy-prepared, not FDA-approved, and its wide availability was tied to shortage status rather than to a separate approval. As the shortage situation for semaglutide changed, the compounding picture changed with it. For how the two compounds differ in mechanism and trial data, see semaglutide vs tirzepatide, and for reported adverse events, the semaglutide side effects page.

Brand, compounded, and research-grade at a glance

The three categories are easy to confuse because they can involve the same active ingredient. They differ on approval status, on whether a prescription is required, and on who they are for. This table names no specific seller and quotes no price.

DimensionBrand (Zepbound, Mounjaro)CompoundedResearch-grade
What it isFDA-approved tirzepatide medicinePharmacy-prepared tirzepatide under the compounding frameworkTirzepatide reference material for laboratory research
Approval statusApproved for named usesNot FDA-approved; permitted under 503A or 503B conditionsNot a medicine; sold for research use only
Prescription requiredYesYesNo; research-use-only terms
OversightFull FDA review of the productPharmacy or outsourcing-facility level, not FDA product reviewThird-party certificate of analysis per batch
Typical buyerPatients via a prescriberPatients via a prescriber, often during access gapsResearchers and labs

For the buyer's view of the prescription and research-grade lanes, and what to verify in each, see where to buy tirzepatide. For a three-way look at the compounds themselves, see tirzepatide vs semaglutide vs retatrutide.

Where Peptara Labs fits

Peptara Labs supplies research-grade peptides for laboratory research use only, and it has sold out of tirzepatide. It is not a pharmacy, it does not compound or dispense medication, and it does not provide medical advice, dosing, or a prescription. What it provides is research-grade material with a third-party certificate of analysis for every batch.

Compounded Tirzepatide: FAQ

Sourcing research-grade peptides?

Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.

General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.